Search

Zentalis Pharmaceuticals Inc

Geschlossen

2.69 -1.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.73

Max

2.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+206.62% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-44M

287M

Vorheriger Eröffnungskurs

4.51

Vorheriger Schlusskurs

2.69

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Sept. 2026, 23:56 UTC

News

EUR/GBP rises as Germany's business expectations for September exceed forecasts, reaching 90.4 and indicating notable strength in today's performance.

24. Sept. 2026, 23:56 UTC

RealReal Inc is trading modestly lower in after-market hours, having retraced from an initial gain and remaining near the lower end of its one-month range.

24. Sept. 2026, 23:56 UTC

Correlated Moves

Carlyle Group Inc is higher in after-market trading, likely moving in sympathy with Brookfield Asset Management amid mixed economic signals.

24. Sept. 2026, 23:56 UTC

Correlated Moves

Targa Resources Corp is trading modestly higher in after-market hours, potentially influenced by Permian Resources Corp's significant recovery from earlier lows.

24. Sept. 2026, 23:56 UTC

Correlated Moves

Jack Henry & Associates Inc traded modestly higher in after-market hours, continuing a stable trend since Thursday's close, influenced by Fidelity National Information Services Inc.

24. Sept. 2026, 23:56 UTC

Baxter International Inc is trading slightly higher in after-market hours, recovering from an earlier decline but remains below its 20-day moving average.

24. Sept. 2026, 23:56 UTC

Correlated Moves

Matador Resources Co is trading lower in after-market hours, reflecting a decline in oil prices and positioned near the lower end of its one-month range.

24. Sept. 2026, 23:56 UTC

Correlated Moves

EMCOR Group Inc is trading lower in after-market hours, continuing a decline over the past four sessions amid broader losses in the Defiance Quantum ETF.

24. Sept. 2026, 23:56 UTC

LKQ Corp saw a modest increase in after-market trading, settling with a cumulative return around 0.25% since Thursday's close, but remains below its 20-day moving average.

24. Sept. 2026, 23:55 UTC

Globalstar Inc is seeing a modest decline in after-market trading, settling near the lower end of its one-month trading range.

24. Sept. 2026, 23:55 UTC

Advanced in after-market trading, supported by strong performance.

24. Sept. 2026, 23:55 UTC

News

LPL Financial reported total client assets of $2.60 trillion for August 2026, with the stock trading modestly lower in after-market hours.

24. Sept. 2026, 23:55 UTC

Event

CarMax Inc shares have moved modestly lower in after-market trading ahead of its Q2 FY2027 earnings report, with EPS expected at $0.70.

24. Sept. 2026, 23:55 UTC

Roivant Sciences Ltd is seeing a slight uptick in after-market hours, despite remaining roughly flat since Thursday's close and below its 20-day moving average.

24. Sept. 2026, 23:55 UTC

CoreCivic Inc is trading lower in after-market hours, continuing a decline since Thursday's close and reflecting notable weakness at the low end of its range.

24. Sept. 2026, 23:55 UTC

Lamb Weston Holdings Inc is trading modestly higher in after-market hours, marking its highest cumulative return since Thursday's close despite recent volatility.

24. Sept. 2026, 23:55 UTC

Hershey Co's shares are trading modestly higher in after-market hours, despite remaining below their 20-day moving average and near the lower end of their one-month range.

24. Sept. 2026, 23:55 UTC

Ascendis Pharma A/S is trading modestly lower in after-market hours, significantly below its 20-day moving average and near the lower end of its one-month trading range.

24. Sept. 2026, 23:55 UTC

Alpha Metallurgical Resources Inc traded modestly higher in after-market hours, though it remains significantly below its 20-day moving average.

24. Sept. 2026, 23:55 UTC

Bank OZK traded modestly higher in after-market hours on Thursday, despite a decline from an earlier high and being below its 20-day moving average.

24. Sept. 2026, 23:55 UTC

Crocs Inc. is trading slightly lower in after-market hours, remaining roughly flat since Thursday's close after briefly peaking nearly 1% above the previous close.

24. Sept. 2026, 23:55 UTC

Franklin Resources Inc is trading modestly lower in after-market hours, marking a fifth consecutive session of declines and remaining below its 20-day moving average.

24. Sept. 2026, 23:55 UTC

News
Social Media

MGM Resorts International shares are modestly lower in after-market trading as it considers a bid for People Incorporated amid uncertain negotiations.

24. Sept. 2026, 23:52 UTC

Mexican Business Confidence Remains Cautious Ahead of September Survey, Stuck Below Neutral Threshold Amid Inflation Concerns.

24. Sept. 2026, 23:52 UTC

UK Consumer Confidence Index Surprises with -13.0, Indicating Resilience Amid Inflationary Pressures

24. Sept. 2026, 23:52 UTC

Upcoming ADP Employment Change report on September 30 raises concerns over declining job growth amid rising bond yields and inflation risks.

24. Sept. 2026, 23:52 UTC

Michigan Consumer Sentiment Index for September 2026 Forecasted at 47.6 Amid Ongoing Economic Concerns and Inflationary Pressures

24. Sept. 2026, 23:51 UTC

Wolfspeed Inc's shares are declining in after-market hours, reflecting broader market weakness amid rising U.S. Treasury yields and inflation concerns.

24. Sept. 2026, 23:51 UTC

Correlated Moves

United Bankshares Inc is trading modestly higher in after-market hours, following gains linked to the Vanguard Morningstar Value ETF and strong performances from key holdings.

24. Sept. 2026, 23:51 UTC

ProPetro Holding Corp is trading higher in after-market hours, showing notable upward movement despite remaining significantly below its 20-day moving average.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

206.62% Vorteil

12-Monats-Prognose

Durchschnitt 8.8 USD  206.62%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.